Source: Annual Congress 2012 - Special problems in thoracic surgery
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
T. Wandtke, M. Jankowski, P. Kopinski, M. Bella, J. Kowalewski, A. Szpechcinski, E. Pólgesek (Bydgoszcz, Warsaw, Poland). Interleukin 27 (IL27): A new tool for lung cancer gene immunotherapy?. Eur Respir J 2012; 40: Suppl. 56, 4419

Member's Comments

No comment yet.

Related content which might interest you: Interleukin 27 (IL27) as a novel therapeutic tool in lung cancer immune therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Late-breaking abstract: Serum concentrations of new factors (IL-20, galectin 3, IL-29 and IL-33) involved in angiogenesis in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011 Immunotherapy (as an adjuvant therapeutic tool) of tuberculosis - does it have a future? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC) Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005 The role of CD40 molecule in human lung cancer and its application in immunotherapy Source: Eur Respir J 2003; 22: Suppl. 45, 199s Year: 2003 Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020 Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Investigation of a relationship between NF-KB1A gene polymorphism and non small cell lung cancer (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10 Source: Eur Respir J 2007; 30: 608-610 Year: 2007 Which gene expression signatures in pharmacogenomic strategies for lung cancer? Source: Annual Congress 2010 - Customised chemotherapy for lung cancer Year: 2010 Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 The role of TNF-α and IL-6 in the development of cancer anorexia - cachexia syndrome (CACS) in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 673s Year: 2004 Gene expression profiling reveal novel biomarkers in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 ALK- and ROS-1-inhibition: a relevant treatment strategy for lung cancer? Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 Role of bronchoscopy in lung cancer translational research: Tumor harvest for the lung cancer mutation consortium (LCMC) studies Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Where next for lung cancer gene expression profiling? Source: Eur Respir J 2007; 30: 5-6 Year: 2007